Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 185-190 , May 2010

Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients

Received 11 March 2009 ,Revised 30 November 2009 ,Accepted 13 February 2010.

References 

  1. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  4. Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, et al. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  5. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–599
  6. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–69
  7. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:921–929
  8. Van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  9. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007;2:36
  10. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol. 2007;61:297–302
  11. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. 2000;55:99–109
  12. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology. 1995;195:385–390
  13. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. RAD. 1999;213:473–480
  14. Van Dorsten FA, van der Graaf M, Engelbrecht MRW, et al. Combined quantitative dynamic contrast-enhanced MR imaging an 1H NMR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20:279–287
  15. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–458
  16. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654–661
  17. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258–262
  18. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging. 2006;23:130–134
  19. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0tesla. Invest Radiol. 2006;41:185–188
  20. Kumar V, Jagannathan NR, R K, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed. 2007;20:505–511
  21. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol. 2007;189:323–328
  22. Padhani AR. Dynamic contrast-enhanced mr in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002;16:407–422
  23. Buckley DL, Roberts C, Parker GJM, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging – initial experience. Radiology. 2004;233:709–715
  24. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis–correlation with biopsy and histopathology. J Magn Reson Imaging. 2006;24:108–113
  25. Franiel T, Lüdemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol. 2008;43:481–487
  26. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. Am J Roentgenol. 2007;189:849
  27. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–125
  28. Pauls S, Mottaghy FM, Schmidt SA, et al. Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. MRI. 2008;26:1334–1341
  29. Palmowski M, Schifferdecker I, Zwick S, et al. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. EJR. 2009;
  30. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Med. 1987;5:201–208
  31. Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging; in press.
  32. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. IR. 2005;40:715–724
  33. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  34. Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med. 2004;51:858–862
  35. Norris DG, Niendorf T. Interpretation of DW-NMR data: dependence on experimental conditions. NMRBio. 1995;8:280–288
  36. Langer DL, Van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2–sparse versus dense cancers. Radiology. 2008;249:900–908
  37. Park H, Piert MR, Khan A, et al. Registration methodology for histological sections and in vivo imaging of human prostate. AR. 2008;15:1027–1039
  38. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  39. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJUint,doi:doi:10.1111/j.1464-410X.2008.08130.x 2008.
  40. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Physiol. 1995;147:9–19

PII: S0167-8140(10)00107-6

doi: 10.1016/j.radonc.2010.02.014

Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 185-190 , May 2010

Article Tools

* Image Usage & Resolution